Céline Ferlay

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial

C. Carrié, Ali Hasbini, Guy de Laroche et al. · The Lancet Oncology · 2016 · 361 citations

Medicine, Oncology, Urology +15

Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial

C. Carrié, Nicolas Magné, Patricia Burban-Provost et al. · The Lancet Oncology · 2019 · 250 citations · Full text

Medicine, Oncology, Urology +16

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

Sylvie Négrier, Gwénaëlle Gravis, David Pérol et al. · The Lancet Oncology · 2011 · 238 citations

Medicine, Oncology, Pharmacotherapy +9

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial

Aude Fléchon, Damien Pouessel, Céline Ferlay et al. · Annals of Oncology · 2011 · 143 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical presentation, evolution, and prognosis of precursor B‐cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951

Stéphane Ducassou, Céline Ferlay, Christophe Bergeron et al. · British Journal of Haematology · 2011 · 102 citations

Medicine, Hematology, Oncology +15